Importantly, the pharmacological inhibition of USP13 sensitizes HPV-positive cervical cancer cells to BH3 mimetic inhibitors, implying that targeting USP13 could be beneficial in the treatment of these tumors [122]. This evidence concerns the gene USP13 and cervical carcinoma.